TC-5619

From Wikipedia, the free encyclopedia
TC-5619
Systematic (IUPAC) name
N-[(2S,3S)-2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide
Clinical data
Legal status ?
Identifiers
ATC code ?
PubChem CID 16727410
UNII UM3821998K YesY
Chemical data
Formula C22H23N3O2 
Mol. mass 361.437
 YesY (what is this?)  (verify)

TC-5619 is a drug developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and is currently being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and Attention Deficit Disorder. [1] Phase I clinical trials have been completed successfully, and it is currently in Phase II trials.[2]

In May 2011, AstraZeneca declined to exercise its right to license the compound. [3]

In September 2012, Targacept ended its development of TC-5619 for the purpose of treating ADHD in adults. [4]

References


This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.